Erectile Dysfunction Drugs Market by Drug (Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra)), Mode of Administration (Injections, Oral, Topical), Distribution Channel - Global Forecast 2024-2030

Erectile Dysfunction Drugs Market by Drug (Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra)), Mode of Administration (Injections, Oral, Topical), Distribution Channel - Global Forecast 2024-2030


The Erectile Dysfunction Drugs Market size was estimated at USD 2.41 billion in 2023 and expected to reach USD 2.59 billion in 2024, at a CAGR 7.41% to reach USD 3.98 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Erectile Dysfunction Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Erectile Dysfunction Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Erectile Dysfunction Drugs Market, highlighting leading vendors and their innovative profiles. These include Adamed Sp. z o.o., Bayer AG, Cipla Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, Endo International PLC, Futura Medical PLC, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novartis International AG, Pfizer Inc., S.K. Chemicals Co. Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vivus, Inc..

Market Segmentation & Coverage

This research report categorizes the Erectile Dysfunction Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug
Avanafil (Stendra)

Muse Suppository (Alprostadil)

Sildenafil (Viagra)

Tadalafil (Cialis)

Vardenafil (Levitra, Staxyn)
Mode of Administration
Injections

Oral

Topical
Distribution Channel
Hospital Pharmacies

Online Pharmacies

Retail Pharmacies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Erectile Dysfunction Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Erectile Dysfunction Drugs Market?
3. What are the technology trends and regulatory frameworks in the Erectile Dysfunction Drugs Market?
4. What is the market share of the leading vendors in the Erectile Dysfunction Drugs Market?
5. Which modes and strategic moves are suitable for entering the Erectile Dysfunction Drugs Market?PDF E-mail From Publisher (2-5)Users License


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Erectile Dysfunction Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase cases of erectile dysfunction among geriatric population
5.1.1.2. Rising adoption of a sedentary lifestyle and incidence of lifestyle diseases
5.1.1.3. Prevalence of non generic drugs and easy availability of OTC ED drugs
5.1.2. Restraints
5.1.2.1. Side effects associated with the erectile dysfunction drugs
5.1.3. Opportunities
5.1.3.1. Increasing advancements and new product launches of ED drugs
5.1.3.2. R&D focused on developments of effective therapies and treatments for erectile dysfunction
5.1.4. Challenges
5.1.4.1. Availability of cost-effective counterfeit drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Erectile Dysfunction Drugs Market, by Drug
6.1. Introduction
6.2. Avanafil (Stendra)
6.3. Muse Suppository (Alprostadil)
6.4. Sildenafil (Viagra)
6.5. Tadalafil (Cialis)
6.6. Vardenafil (Levitra, Staxyn)
7. Erectile Dysfunction Drugs Market, by Mode of Administration
7.1. Introduction
7.2. Injections
7.3. Oral
7.4. Topical
8. Erectile Dysfunction Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Erectile Dysfunction Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Erectile Dysfunction Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Erectile Dysfunction Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Adamed Sp. z o.o.
13.1.2. Bayer AG
13.1.3. Cipla Limited
13.1.4. Dr. Reddys Laboratories Ltd.
13.1.5. Eli Lilly and Company
13.1.6. Endo International PLC
13.1.7. Futura Medical PLC
13.1.8. GlaxoSmithKline PLC
13.1.9. Johnson & Johnson Services, Inc.
13.1.10. Novartis International AG
13.1.11. Pfizer Inc.
13.1.12. S.K. Chemicals Co. Ltd.
13.1.13. Sanofi S.A.
13.1.14. Sun Pharmaceutical Industries Ltd.
13.1.15. Teva Pharmaceutical Industries Ltd.
13.1.16. Vivus, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. ERECTILE DYSFUNCTION DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ERECTILE DYSFUNCTION DRUGS MARKET DYNAMICS
FIGURE 7. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 8. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings